MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 236.54 Billion KRW | 2.65% |
| 2022 | 230.44 Billion KRW | 3.22% |
| 2021 | 223.26 Billion KRW | -8.13% |
| 2020 | 243.02 Billion KRW | -8.1% |
| 2019 | 264.44 Billion KRW | 8.79% |
| 2018 | 243.06 Billion KRW | 3.4% |
| 2017 | 235.07 Billion KRW | 6.33% |
| 2016 | 221.07 Billion KRW | 10.86% |
| 2015 | 199.41 Billion KRW | 4.59% |
| 2014 | 190.66 Billion KRW | -0.91% |
| 2013 | 192.41 Billion KRW | 2.16% |
| 2012 | 188.33 Billion KRW | -7.0% |
| 2011 | 202.5 Billion KRW | 23.36% |
| 2010 | 164.15 Billion KRW | 6.7% |
| 2009 | 153.84 Billion KRW | 57.86% |
| 2008 | 97.45 Billion KRW | 64.15% |
| 2007 | 59.36 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 239.59 Billion KRW | 3.21% |
| 2024 Q1 | 232.14 Billion KRW | -1.86% |
| 2023 Q2 | 235.8 Billion KRW | 1.54% |
| 2023 FY | 236.54 Billion KRW | 2.65% |
| 2023 Q1 | 232.22 Billion KRW | 0.77% |
| 2023 Q4 | 236.54 Billion KRW | -0.2% |
| 2023 Q3 | 237.02 Billion KRW | 0.52% |
| 2022 Q2 | 222.09 Billion KRW | -0.56% |
| 2022 Q4 | 230.44 Billion KRW | 3.01% |
| 2022 Q1 | 223.35 Billion KRW | 0.04% |
| 2022 FY | 230.44 Billion KRW | 3.22% |
| 2022 Q3 | 223.71 Billion KRW | 0.73% |
| 2021 Q1 | 240.3 Billion KRW | -1.12% |
| 2021 Q2 | 234.62 Billion KRW | -2.36% |
| 2021 FY | 223.26 Billion KRW | -8.13% |
| 2021 Q4 | 223.26 Billion KRW | -3.59% |
| 2021 Q3 | 231.57 Billion KRW | -1.3% |
| 2020 FY | 243.02 Billion KRW | -8.1% |
| 2020 Q1 | 258.57 Billion KRW | -2.22% |
| 2020 Q4 | 243.02 Billion KRW | -8.17% |
| 2020 Q3 | 264.64 Billion KRW | -3.95% |
| 2020 Q2 | 275.52 Billion KRW | 6.55% |
| 2019 Q1 | 258.79 Billion KRW | 6.47% |
| 2019 Q4 | 264.44 Billion KRW | 2.06% |
| 2019 Q3 | 259.09 Billion KRW | 0.74% |
| 2019 Q2 | 257.19 Billion KRW | -0.62% |
| 2019 FY | 264.44 Billion KRW | 8.79% |
| 2018 Q1 | 241.69 Billion KRW | 2.82% |
| 2018 Q3 | 242.34 Billion KRW | 2.01% |
| 2018 Q4 | 243.06 Billion KRW | 0.3% |
| 2018 FY | 243.06 Billion KRW | 3.4% |
| 2018 Q2 | 237.58 Billion KRW | -1.7% |
| 2017 Q4 | 235.07 Billion KRW | 5.81% |
| 2017 Q3 | 222.16 Billion KRW | 0.23% |
| 2017 Q2 | 221.65 Billion KRW | 2.52% |
| 2017 Q1 | 216.21 Billion KRW | -2.2% |
| 2017 FY | 235.07 Billion KRW | 6.33% |
| 2016 FY | 221.07 Billion KRW | 10.86% |
| 2016 Q1 | 203.19 Billion KRW | 1.89% |
| 2016 Q2 | 201.85 Billion KRW | -0.66% |
| 2016 Q3 | 216.35 Billion KRW | 7.18% |
| 2016 Q4 | 221.07 Billion KRW | 2.18% |
| 2015 Q1 | 194.2 Billion KRW | 1.86% |
| 2015 Q2 | 191.33 Billion KRW | -1.48% |
| 2015 Q4 | 199.41 Billion KRW | 1.26% |
| 2015 FY | 199.41 Billion KRW | 4.59% |
| 2015 Q3 | 196.94 Billion KRW | 2.93% |
| 2014 Q2 | 190.24 Billion KRW | -0.88% |
| 2014 FY | 190.66 Billion KRW | -0.91% |
| 2014 Q4 | 190.66 Billion KRW | 2.9% |
| 2014 Q3 | 185.29 Billion KRW | -2.6% |
| 2014 Q1 | 191.92 Billion KRW | -0.25% |
| 2013 Q1 | 193.16 Billion KRW | 2.56% |
| 2013 Q3 | 192.43 Billion KRW | -1.96% |
| 2013 Q4 | 192.41 Billion KRW | -0.01% |
| 2013 FY | 192.41 Billion KRW | 2.16% |
| 2013 Q2 | 196.28 Billion KRW | 1.62% |
| 2012 Q4 | 188.33 Billion KRW | 0.0% |
| 2012 Q1 | 172.45 Billion KRW | 0.0% |
| 2012 FY | 188.33 Billion KRW | -7.0% |
| 2011 FY | 202.5 Billion KRW | 23.36% |
| 2011 Q3 | 168 Billion KRW | 2.18% |
| 2011 Q2 | 164.41 Billion KRW | 0.24% |
| 2011 Q1 | 164.02 Billion KRW | 0.0% |
| 2010 Q2 | 119.99 Billion KRW | 0.63% |
| 2010 Q1 | 119.24 Billion KRW | 0.0% |
| 2010 Q3 | 124.43 Billion KRW | 3.7% |
| 2010 FY | 164.15 Billion KRW | 6.7% |
| 2009 Q1 | 103.4 Billion KRW | 6.1% |
| 2009 FY | 153.84 Billion KRW | 57.86% |
| 2009 Q3 | 119.45 Billion KRW | 4.25% |
| 2009 Q2 | 114.58 Billion KRW | 10.82% |
| 2008 Q2 | 65.76 Billion KRW | 0.0% |
| 2008 Q3 | 76.41 Billion KRW | 16.2% |
| 2008 FY | 97.45 Billion KRW | 64.15% |
| 2008 Q4 | 97.45 Billion KRW | 27.53% |
| 2007 FY | 59.36 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -19.34% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 87.913% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 73.027% |
| HANDOK Inc. | 790.33 Billion KRW | 70.07% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -38.641% |
| Yuhan Corporation | 2814.07 Billion KRW | 91.594% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 82.015% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -153.05% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 87.882% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 1.334% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 49.553% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -105.742% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 32.102% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -19.34% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 43.57% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 52.669% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 59.866% |
| JW Holdings Corporation | 1176.26 Billion KRW | 79.89% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 61.301% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 83.133% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 63.328% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 32.431% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -53.562% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 36.185% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 51.46% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -19.34% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 78.058% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 86.638% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 63.328% |
| Yuhan Corporation | 2814.07 Billion KRW | 91.594% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 73.119% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -4.39% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 76.196% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 63.328% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 43.666% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 49.548% |
| CKD Bio Corp. | 293.78 Billion KRW | 19.482% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 53.435% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 58.131% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 41.044% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 32.431% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 83.754% |
| Boryung Corporation | 922.36 Billion KRW | 74.354% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 46.538% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 49.553% |
| JW Lifescience Corporation | 255.83 Billion KRW | 7.539% |